Literature DB >> 12749532

Optimal scheduling of radiotherapy and angiogenic inhibitors.

Ayla Ergun1, Kevin Camphausen, Lawrence M Wein.   

Abstract

We incorporate a previously validated mathematical model of a vascularized tumor into an optimal control problem to determine the temporal scheduling of radiotherapy and angiogenic inhibitors that maximizes the control of a primary tumor. Our results reveal that optimal antiangiogenic monotherapy gives a large initial injection to attain a 20:1 ratio of tumor cell volume to supporting vasculature volume. It thereafter maintains this 20:1 ratio via a continuous dose rate that is intensified over time. The optimal radiation monotherapy schedule is characterized by a modest dose intensification over time. The best performance is achieved by our optimal combination regimen, where the antiangiogenic treatment again maintains a constant tumor-to-vasculature ratio, but is administered in a dose-intensified manner only during the latter portion of the radiation fractionation schedule.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12749532     DOI: 10.1016/S0092-8240(03)00006-5

Source DB:  PubMed          Journal:  Bull Math Biol        ISSN: 0092-8240            Impact factor:   1.758


  8 in total

1.  Dynamical properties of a minimally parameterized mathematical model for metronomic chemotherapy.

Authors:  Heinz Schättler; Urszula Ledzewicz; Behrooz Amini
Journal:  J Math Biol       Date:  2015-06-19       Impact factor: 2.259

2.  Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics.

Authors:  Urszula Ledzewicz; Mohammad Naghnaeian; Heinz Schättler
Journal:  J Math Biol       Date:  2011-05-08       Impact factor: 2.259

Review 3.  Mathematical modeling as a tool for planning anticancer therapy.

Authors:  Andrzej Swierniak; Marek Kimmel; Jaroslaw Smieja
Journal:  Eur J Pharmacol       Date:  2009-10-13       Impact factor: 4.432

4.  Comparison of simple models of periodic protocols for combined anticancer therapy.

Authors:  Marzena Dołbniak; Andrzej Swierniak
Journal:  Comput Math Methods Med       Date:  2013-04-07       Impact factor: 2.238

5.  Therapeutic implications from sensitivity analysis of tumor angiogenesis models.

Authors:  Jan Poleszczuk; Philip Hahnfeldt; Heiko Enderling
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

6.  Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1.

Authors:  S M Sagar; D Yance; R K Wong
Journal:  Curr Oncol       Date:  2006-02       Impact factor: 3.677

7.  Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data.

Authors:  Katerina D Argyri; Dimitra D Dionysiou; Fay D Misichroni; Georgios S Stamatakos
Journal:  Biol Direct       Date:  2016-03-22       Impact factor: 4.540

Review 8.  Optimal Control Theory for Personalized Therapeutic Regimens in Oncology: Background, History, Challenges, and Opportunities.

Authors:  Angela M Jarrett; Danial Faghihi; David A Hormuth Ii; Ernesto A B F Lima; John Virostko; George Biros; Debra Patt; Thomas E Yankeelov
Journal:  J Clin Med       Date:  2020-05-02       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.